Author
EF. Domino
Dr.Antonio Esteve Foundation
TORRE ESTEVEPasseig de la Zona Franca, 109
08038 Barcelona
Tel:
93 433 53 20
E-mail:
fundacion@esteve.org
The third volume of Pharmacology Revisited: an Esteve Foundation Series gathers 33 articles related to psychopharmacology. In Selected publications shaping psychopharmacology as a discipline, professor Edward F. Domino, from the Department of Pharmacology of the University of Michigan, compiled the most relevant texts in this field published in journals like The Lancet, Pharmacology & Toxicology or The Medical Journal of Australia. As is usual in this Esteve Foundation’s series, a facsimile edition of these articles is provided.
Full document | ||
Full PDF | EF. Domino | [wpdm type=”btn3″] |
Chapters | ||
Acknowledgements | [wpdm id=23 type=”btn”] | |
Introduction | EF. Domino | [wpdm id=21 type=”btn”] |
Reference list | [wpdm id=22 type=”btn”] | |
Index | [wpdm id=20 type=”btn”] | |
1. Un nouveau stabilisateur végétatif (LE 4560 RP) | H. Laborit / P. Huguenard / R. Allaume | [wpdm type=”btn3″] |
2. Utilisation en thérapeutique psychiatrique d\’une phénothiazine d\’action centrale élective (4560 RP) | J. Delay / P. Deniker / JM. Harl | [wpdm type=”btn3″] |
3. Propriétés pharmacodynamiques du chlorhydrate de chloro-3 (diméthylamino-3\’ propyl)-10 phénothiazine (4.560 R.P.) | S. Courvoisier / J. Fournel / R. Ducrot / M. Kolsky / P. Koetschet | [wpdm type=”btn3″] |
4. A controlled clinical test of a new psycholeptic drug (haloperidol) | E. Brandrup / P. Kristjansen | [wpdm type=”btn3″] |
5. The butyrophenone story | PAJ. Janssen | [wpdm type=”btn3″] |
6. Antipsychotic drug doses and neuroleptic/dopamine receptors | P. Seeman / T. Lee / M. Chau-Wong / K. Wong | [wpdm type=”btn3″] |
7. The current status of the dopamine hypothesis of schizophrenia | A. Carlsson | [wpdm type=”btn3″] |
8. Comments and reply on \”The current status of the dopamine hypothesis of schizophrenia\” | DF. Klein / AJ. Friedhoff / HY. Meltzer / SH. Snyder / A. Carlsson | [wpdm type=”btn3″] |
9. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine | J. Kane / G. Honigfeld / J. Singer / H. Meltzer / Clozaril Collaborative Study Group | [wpdm type=”btn3″] |
10. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia | HY. Meltzer | [wpdm type=”btn3″] |
11. Iproniazid (Marsilid®) phosphate, a therapeutic agent for mental disorders and debilitating diseases | GE. Crane | [wpdm type=”btn3″] |
12. The treatment of depressive states with G 22355 (imipramine hydrochloride) | R. Kuhn | [wpdm type=”btn3″] |
13. A concept for a role of serotonin and norepinephrine as chemical mediators in the brain | BB. Brodie / PA. Shore | [wpdm type=”btn3″] |
14. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect | IP. Lapin / GF. Oxenkrug | [wpdm type=”btn3″] |
15. Initial clinical trial based on biochemical methodology of zimelidine (a serotonin uptake inhibitor) in depressed patients | B. Siwers / VA. Ringberger / JR. Tuck / F. Sjöqvist | [wpdm type=”btn3″] |
16. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy)-N-ethyl-3-phenylpropylamine | DT. Wong / FP. Bymaster / JS. Horng / BB. Molloy | [wpdm type=”btn3″] |
17. The psychosedative properties of methaminodiazepoxide | LO. Randall / GAH. Schallek / EF. Keith / RE. Bagdon | [wpdm type=”btn3″] |
18. Tolerance development with chlordiazepoxide in relation to the plasma levels of the parent compound and its main metabolites in mice | JD. Christensen | [wpdm type=”btn3″] |
19. Selective antagonists of benzodiazepines | W. Hunkeler / H. Möhler / L. Pieri / P. Polc / EP. Bonetti / R. Cumin / R. Schaffner / W. Haefely | [wpdm type=”btn3″] |
20. New concepts on the mechanism of action of benzodiazepines | E. Costa / A. Guidotti / CC. Mao / A. Suria | [wpdm type=”btn3″] |
21. Lithium salts in the treatment of psychotic excitement | JFJ. Cade | [wpdm type=”btn3″] |
22. The treatment of manic psychoses by the administration of lithium salts | M. Schou / N. Juel-Nielsen / E. Strömgren / H. Voldby | [wpdm type=”btn3″] |
23. Lithium as a prophylactic agent: Its effect against recurrent depressions and manic-depressive psychosis | PC. Baastrup / M. Schou | [wpdm type=”btn3″] |
24. N-allyl-norcodeine and N-allyl-normorphine, two antagonists to morphine | ER. Hart | [wpdm type=”btn3″] |
25. A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride | VP. Dole / M. Nyswander | [wpdm type=”btn3″] |
26. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain | A. Goldstein / LI. Lowney / BK. Pal | [wpdm type=”btn3″] |
27. Opiate receptor: Demonstration in nervous tissue | CB. Pert / SH. Snyder | [wpdm type=”btn3″] |
28. Identification of two related pentapeptides from the brain with potent opiate agonist activity | J. Hughes / TW. Smith / HW. Kosterlitz / LA. Fothergill / BA. Morgan / HR. Morris | [wpdm type=”btn3″] |
29. Determination and characterization of a cannabinoid receptor in rat brain | WA. Devane / FA. Dysarz III / M. Ross Johnson / LS. Melvin / AC. Howlett | [wpdm type=”btn3″] |
30. Psychotomimetic drugs: Chemical and pharmacological aspects | A. Hofmann | [wpdm type=”btn3″] |
31. Study of a new schizophrenomimetic drug – Sernyl | ED. Luby / BD. Cohen / G. Rosenbaum / JS. Gottlieb / R. Kelley | [wpdm type=”btn3″] |
32. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man | EF. Domino / P. Chodoff / G. Corssen | [wpdm type=”btn3″] |
33. Dynamics of drug dependence: Implications of a conditioning theory for research and treatment | A. Wikler | [wpdm type=”btn3″] |
34. Self-administration of psychoactive substances by the monkey: A measure of psychological dependence | G. Deneau / T. Yanagita / MH. Seevers | [wpdm type=”btn3″] |
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information. Les cookies necessàries són absolutament essencials perquè el lloc web funcioni correctament. Aquesta categoria només inclou galetes que garanteixen funcionalitats bàsiques i funcions de seguretat del lloc web. Aquestes cookies no emmagatzemen cap informació personal. Las cookies necesarias son absolutamente esenciales para que el sitio web funcione correctamente. Esta categoría solo incluye cookies que garantizan funcionalidades básicas y características de seguridad del sitio web. Estas cookies no almacenan ninguna información personal.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website. Totes les galetes que poden no ser especialment necessàries perquè el lloc web funcioni i s’utilitzen específicament per recopilar dades personals de l’usuari mitjançant analítiques, anuncis i altres continguts incrustats s’anomenen cookies no necessàries. És obligatori obtenir el consentiment de l'usuari abans d'executar aquestes cookies al vostre lloc web. Las cookies que pueden no ser particularmente necesarias para el funcionamiento del sitio web y que se utilizan específicamente para recopilar datos personales del usuario a través de análisis, anuncios y otros contenidos integrados se denominan cookies no necesarias. Es obligatorio obtener el consentimiento del usuario antes de ejecutar estas cookies en su sitio web.